7 Questions CTL019 Adcom Should Consider (And 2 It Won’t) – Seeking Alpha
|
7 Questions CTL019 Adcom Should Consider (And 2 It Won't)
Seeking Alpha Here a single dose of CAR–T cells put 83% of successfully infused subjects into complete remission – a striking finding given that 56% had failed stem cell transplant, and patients overall had progressed after one to eight lines of prior therapy … |
